Microdrop Human Immunodeficiency Virus Sequencing for Incidence and Drug Resistance Surveillance
Open Access
- 31 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 224 (6), 1048-1059
- https://doi.org/10.1093/infdis/jiab060
Abstract
Precise and cost-efficient human immunodeficiency virus (HIV) incidence and drug resistance surveillances are in high demand for the advancement of the 90-90-90 “treatment for all” target. We developed microdrop HIV sequencing for the HIV incidence and drug resistance assay (HIDA), a single-blood-draw surveillance tool for incidence and drug resistance mutation (DRM) detection. We amplified full-length HIV envelope and pol gene sequences within microdroplets, and this compartmental amplification with long-read high-throughput sequencing enabled us to recover multiple unique sequences. We achieved greater precision in determining the stage of infection than current incidence assays, with a 1.2% false recency rate (proportion of misclassified chronic infections) and a 262-day mean duration of recent infection (average time span of recent infection classification) from 83 recently infected and 81 chronically infected individuals. Microdrop HIV sequencing demonstrated an increased capacity to detect minority variants and linked DRMs. By screening all 93 World Health Organization surveillance DRMs, we detected 6 pretreatment drug resistance mutations with 2.6%–13.2% prevalence and cross-linked mutations. HIDA with microdrop HIV sequencing may promote global HIV real-time surveillance by serving as a precise and high-throughput cross-sectional survey tool that can be generalized for surveillance of other pathogens.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (R01-AI095066)
- Bill & Melinda Gates Foundation (OPP1017716, OPP1062806, OPP1115799)
This publication has 40 references indexed in Scilit:
- Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillancePLOS ONE, 2019
- Success and failure of initial antiretroviral therapy in adultsAIDS, 2019
- Assessing Estimates of HIV Incidence with a Recent Infection Testing Algorithm That Includes Viral Load Testing and Exposure to Antiretroviral TherapyAIDS Research and Human Retroviruses, 2018
- HIITE: HIV-1 incidence and infection time estimatorBioinformatics, 2018
- The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance StandardsScientific Reports, 2017
- Viral load criteria and threshold optimization to improve HIV incidence assay characteristicsAIDS, 2016
- Developing High-Throughput HIV Incidence Assay with Pyrosequencing PlatformJournal of Virology, 2014
- Rates of Emergence of HIV Drug Resistance in Resource-Limited Settings: A Systematic ReviewAntiviral Therapy, 2013
- Designing a genome-based HIV incidence assay with high sensitivity and specificityAIDS, 2011
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences of the United States of America, 2008